I think Denusomab increases risk of infection not alendronate
Denusomab is RANKL inhibitor and Osteoclast deactivator. Both Denusomab and alendronate cause osteoclastic deactivation. But only Denusomab cause increased risk of infection in the form of Cellulitis . Reason being RANKL Inhibition by Denusomab not only causes RANKL Inhibition of Osteoclast but it calso causes inhibition of RANKL on T cells and Dendritic cells of immune system ----- Decreased Immune system --- Increased Risk of Infection especially in CKD Elderly and DM Patients